PCVX
$65.68+8.01%
as of close, Nov 4, 2026
☾ AH $65.68 +8.01%
Vaxcyte Inc.Stock · HealthcareRussell 2000 · 0.2% of IWMNasdaq Composite · 0.02% of ONEQUS Stock Market · 0.01% of VTIRussell 3000 · 0.01% of IWV
Head-to-head:Compare with ALNY or any ticker →
PCVX SEC filings (2026)
CIK 1649094 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
767 filings on EDGAR since 2015 · 6 annual, 20 quarterly, 69 current · financial statements · earnings
Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Nov 4, 2026
quarter to Sep 30, 2026
Latest 8-K
Nov 4, 2026
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Last earnings release
Nov 4, 2026
8-K, Item 2.02
Filings on file
767
since 2015, 546 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
November 2026
- Nov 4ReportQuarterly report, Q3 2026 — net income −$297.1M, EPS −$1.99
- Nov 48-K8-K · Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business UpdateResults of operations
- Nov 2Insider saleCowan Elvia (SVP, Finance & CAO) sold 3,000 shares for $183K at $60.77–$61.55 under a 10b5-1 plan
- Nov 2Insider saleWassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares for $137K at $60.78–$61.57 under a 10b5-1 plan
October 2026
- Oct 98-K8-K · Material definitive agreement; New financial obligation; Other events
- Oct 5Insider saleCowan Elvia (SVP, Finance & CAO) sold 19,000 shares for $1.6M at $86.74 under a 10b5-1 plan
- Oct 5Insider saleWassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares for $1.6M at $86.74 under a 10b5-1 plan
- Oct 58-K8-K · Regulation FD disclosure; Other events
- Oct 1Insider saleWassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares for $128K at $56.65–$57.09 under a 10b5-1 plan
September 2026
- Sep 9Insider saleWassil Jim (EVP, Chief Scientific Ofc, COO) sold 1,334 shares for $79K at $59.52
- Sep 4Insider saleWassil Jim (EVP, Chief Scientific Ofc, COO) sold 1,381 shares for $84K at $61.16
- Sep 38-K8-K · Directors or officers; compensation; Regulation FD disclosure
- Sep 1Insider saleWassil Jim (CHIEF OPERATING OFFICER) sold 3,477 shares for $212K at $60.89–$61.48
August 2026
- Aug 5EarningsEarnings release — EPS −$1.97 vs −$1.47 est. (−34.0%) 5.3%
- Aug 5ReportQuarterly report, Q2 2026 — net income −$284.3M, EPS −$1.97
- Aug 5Insider saleDhaliwal Harpreet S. (Chief Technical Ops Officer) sold 17,000 shares for $935K at $55.00 under a 10b5-1 plan
- Aug 3Insider saleGUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares for $539K at $53.76–$54.18 under a 10b5-1 plan
- Aug 3Insider saleWassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares for $121K at $53.50–$54.09 under a 10b5-1 plan
July 2026
- Jul 27Insider salePICKERING GRANT (CHIEF EXECUTIVE OFFICER · Director) sold 18,198 shares for $1.0M at $55.52–$55.96 under a 10b5-1 plan
- Jul 158-K8-K · Directors or officers; compensation
- Jul 6Insider saleGUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares for $573K at $57.16–$57.76 under a 10b5-1 plan
- Jul 1Insider saleWassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares for $127K at $56.03–$57.82 under a 10b5-1 plan
June 2026
- Jun 26Insider salePICKERING GRANT (CHIEF EXECUTIVE OFFICER · Director) sold 24,237 shares for $1.3M at $54.22–$56.27 under a 10b5-1 plan
- Jun 238-K8-K · Directors or officers; compensation
- Jun 18Insider salePICKERING GRANT (CHIEF EXECUTIVE OFFICER · Director) sold 24,461 shares for $1.3M at $52.50–$52.51 under a 10b5-1 plan
- Jun 18Insider saleGUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares for $530K at $53.00 under a 10b5-1 plan
- Jun 168-K8-K · Shareholder vote results
- Jun 1Insider saleWassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares for $111K at $49.40–$50.26 under a 10b5-1 plan
May 2026
April 2026
- Apr 23ProxyProxy · Annual report to shareholders
- Apr 23ProxyProxy · Additional proxy materials
- Apr 23ProxyProxy · Proxy statement
- Apr 7Insider saleCowan Elvia (SVP, Finance & CAO) sold 3,000 shares for $180K at $60.00 under a 10b5-1 plan
- Apr 1Insider saleWassil Jim (CHIEF OPERATING OFFICER) sold 2,250 shares for $131K at $58.14–$58.93 under a 10b5-1 plan
March 2026
- Mar 17Insider saleCowan Elvia (SVP, Finance & CAO) sold 1,892 shares for $105K at $55.39–$56.26 under a 10b5-1 plan
- Mar 11Insider saleCowan Elvia (SVP, Finance & CAO) sold 2,500 shares for $146K at $58.59 under a 10b5-1 plan
- Mar 10Insider saleWassil Jim (CHIEF OPERATING OFFICER) sold 7,395 shares for $435K at $58.32–$59.16 under a 10b5-1 plan
February 2026
- Feb 24EarningsEarnings release — EPS −$1.80 vs −$1.46 est. (−23.3%) 2.8%
- Feb 24ReportAnnual report, FY2025 — net income −$766.6M, EPS −$5.63
- Feb 248-K8-K · Other events
- Feb 28-K8-K · Other events
December 2025
- Dec 31Insider saleDhaliwal Harpreet S. (Chief Technical Ops Officer) sold 9,743 shares for $455K at $46.69
- Dec 198-K8-K · Directors or officers; compensation
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $12.2M in 25 sales and bought nothing on the open market; 100 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Nov 2, 2026Form 4 | Cowan ElviaSVP, Finance & CAOSold · $183K · 3,000 sh · 10b5-1 |
| Nov 2, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOSold · $137K · 2,250 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Cowan ElviaSVP, Finance & CAOSold · $1.6M · 19,000 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOSold · $1.6M · 18,000 sh · 10b5-1 |
| Oct 1, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOSold · $128K · 2,250 sh · 10b5-1 |
| Sep 9, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOSold · $79K · 1,334 sh |
| Sep 4, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOSold · $84K · 1,381 sh |
| Sep 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $212K · 3,477 sh |
| Aug 5, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerSold · $935K · 17,000 sh · 10b5-1 |
| Aug 3, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOSold · $539K · 10,000 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $121K · 2,250 sh · 10b5-1 |
| Jul 27, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorSold · $1.0M · 18,198 sh · 10b5-1 |
| Jul 6, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOSold · $573K · 10,000 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $127K · 2,250 sh · 10b5-1 |
| Jun 26, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorSold · $1.3M · 24,237 sh · 10b5-1 |
| Jun 18, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorSold · $1.3M · 24,461 sh · 10b5-1 |
| Jun 18, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOSold · $530K · 10,000 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $111K · 2,250 sh · 10b5-1 |
| May 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $128K · 2,250 sh · 10b5-1 |
| Apr 7, 2026Form 4 | Cowan ElviaSVP, Finance & CAOSold · $180K · 3,000 sh · 10b5-1 |
| Apr 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $131K · 2,250 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Cowan ElviaSVP, Finance & CAOSold · $105K · 1,892 sh · 10b5-1 |
| Mar 11, 2026Form 4 | Cowan ElviaSVP, Finance & CAOSold · $146K · 2,500 sh · 10b5-1 |
| Mar 10, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERSold · $435K · 7,395 sh · 10b5-1 |
| Dec 31, 2025Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerSold · $455K · 9,743 sh |
Awards, exercises, withholding and plan purchases · 100 transactions
| Date | Insider |
|---|---|
| Nov 2, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · $78K · 3,000 sh · 10b5-1 |
| Nov 2, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOExercise or conversion · $12K · 2,250 sh · 10b5-1 |
| Nov 2, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · Stock Option (right to buy) · $0 · 3,000 sh · 10b5-1 |
| Nov 2, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOExercise or conversion · Stock Option (right to buy) · $0 · 2,250 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · $492K · 19,000 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOExercise or conversion · $96K · 18,000 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · Stock Option (right to buy) · $0 · 19,000 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOExercise or conversion · Stock Option (right to buy) · $0 · 18,000 sh · 10b5-1 |
| Oct 1, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOExercise or conversion · $12K · 2,250 sh · 10b5-1 |
| Oct 1, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOExercise or conversion · Stock Option (right to buy) · $0 · 2,250 sh · 10b5-1 |
| Sep 8, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorTax withholding · $1.0M · 17,056 sh |
| Sep 8, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerTax withholding · $462K · 7,651 sh |
| Sep 8, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOTax withholding · $432K · 7,155 sh |
| Sep 8, 2026Form 4 | Wassil JimEVP, Chief Scientific Ofc, COOTax withholding · $330K · 5,459 sh |
| Sep 8, 2026Form 4 | Cowan ElviaSVP, Finance & CAOTax withholding · $80K · 1,327 sh |
| Sep 4, 2026Form 4 | Jodar LuisChief Medical OfficerAward · Stock Option (right to buy) · $0 · 88,254 sh |
| Sep 4, 2026Form 4 | Jodar LuisChief Medical OfficerAward · $0 · 52,632 sh |
| Sep 2, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorTax withholding · $211K · 3,427 sh |
| Sep 2, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOTax withholding · $88K · 1,432 sh |
| Sep 2, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERTax withholding · $88K · 1,432 sh |
| Sep 2, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerTax withholding · $41K · 659 sh |
| Sep 2, 2026Form 4 | Cowan ElviaSVP, Finance & CAOTax withholding · $20K · 326 sh |
| Sep 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERExercise or conversion · $12K · 2,250 sh |
| Sep 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERExercise or conversion · Stock Option (right to buy) · $0 · 2,250 sh |
| Aug 31, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorTax withholding · $174K · 2,862 sh |
| Aug 31, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOTax withholding · $77K · 1,273 sh |
| Aug 31, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERTax withholding · $77K · 1,273 sh |
| Aug 31, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerTax withholding · $22K · 361 sh |
| Aug 31, 2026Form 4 | Cowan ElviaSVP, Finance & CAOTax withholding · $15K · 243 sh |
| Aug 5, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerExercise or conversion · $421K · 17,000 sh · 10b5-1 |
| Aug 5, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerExercise or conversion · Stock Option (right to buy) · $0 · 17,000 sh · 10b5-1 |
| Aug 3, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOExercise or conversion · $54K · 10,000 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERExercise or conversion · $12K · 2,250 sh · 10b5-1 |
| Aug 3, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOExercise or conversion · Stock Option (right to buy) · $0 · 10,000 sh · 10b5-1 |
| Aug 3, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERExercise or conversion · Stock Option (right to buy) · $0 · 2,250 sh · 10b5-1 |
| Jul 27, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorExercise or conversion · $33K · 16,198 sh · 10b5-1 |
| Jul 27, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 16,198 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Markels JohnDirectorAward · Stock Option (right to buy) · $0 · 23,029 sh |
| Jul 6, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOExercise or conversion · $54K · 10,000 sh · 10b5-1 |
| Jul 6, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOExercise or conversion · Stock Option (right to buy) · $0 · 10,000 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERExercise or conversion · $2,761 · 516 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERExercise or conversion · Stock Option (right to buy) · $0 · 516 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Slaoui MoncefDirectorAward · Stock Option (right to buy) · $0 · 26,061 sh |
| Jun 18, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOExercise or conversion · $54K · 10,000 sh · 10b5-1 |
| Jun 18, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorExercise or conversion · $403 · 225 sh · 10b5-1 |
| Jun 18, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOExercise or conversion · Stock Option (right to buy) · $0 · 10,000 sh · 10b5-1 |
| Jun 18, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 225 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Drapeau Anne SDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | Lukatch HeathDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | Gilbert Halley EDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | Paya Carlos VDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | Furey JohnDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | Loxam TeriDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | Lee JacksDirectorAward · Stock Option (right to buy) · $0 · 11,389 sh |
| Jun 15, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · Stock Option (right to buy) · $0 · 11,034 sh |
| Jun 15, 2026Form 4 | Drapeau Anne SDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | Lukatch HeathDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | Gilbert Halley EDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | Paya Carlos VDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | Furey JohnDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | Loxam TeriDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | Lee JacksDirectorAward · $0 · 2,265 sh |
| Jun 15, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · $0 · 2,194 sh |
| Apr 7, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · $78K · 3,000 sh · 10b5-1 |
| Apr 7, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · Stock Option (right to buy) · $0 · 3,000 sh · 10b5-1 |
| Mar 11, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · $65K · 2,500 sh · 10b5-1 |
| Mar 11, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · Stock Option (right to buy) · $0 · 2,500 sh · 10b5-1 |
| Mar 9, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorTax withholding · $219K · 3,685 sh |
| Mar 9, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOTax withholding · $61K · 1,021 sh |
| Mar 9, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERTax withholding · $58K · 975 sh · 10b5-1 |
| Mar 9, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerTax withholding · $36K · 604 sh |
| Mar 9, 2026Form 4 | Cowan ElviaSVP, Finance & CAOTax withholding · $29K · 495 sh · 10b5-1 |
| Mar 2, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorTax withholding · $157K · 2,531 sh |
| Mar 2, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOTax withholding · $63K · 1,009 sh |
| Mar 2, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERTax withholding · $63K · 1,009 sh |
| Mar 2, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerTax withholding · $29K · 465 sh |
| Mar 2, 2026Form 4 | Cowan ElviaSVP, Finance & CAOTax withholding · $20K · 326 sh |
| Feb 28, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorTax withholding · $177K · 2,863 sh |
| Feb 28, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOTax withholding · $56K · 898 sh |
| Feb 28, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERTax withholding · $56K · 898 sh |
| Feb 28, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerTax withholding · $18K · 292 sh |
| Feb 28, 2026Form 4 | Cowan ElviaSVP, Finance & CAOTax withholding · $15K · 243 sh |
| Feb 27, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERAward · $315K · 5,102 sh |
| Feb 27, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERTax withholding · $117K · 1,900 sh |
| Feb 26, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · $200K · 7,716 sh |
| Feb 26, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorAward · Stock Option (right to buy) · $0 · 175,698 sh |
| Feb 26, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorAward · $0 · 105,110 sh |
| Feb 26, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOAward · Stock Option (right to buy) · $0 · 74,993 sh |
| Feb 26, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERAward · Stock Option (right to buy) · $0 · 53,566 sh |
| Feb 26, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerAward · $0 · 53,409 sh |
| Feb 26, 2026Form 4 | Dhaliwal Harpreet S.Chief Technical Ops OfficerAward · Stock Option (right to buy) · $0 · 46,424 sh |
| Feb 26, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOAward · $0 · 44,864 sh |
| Feb 26, 2026Form 4 | Wassil JimCHIEF OPERATING OFFICERAward · $0 · 32,045 sh |
| Feb 26, 2026Form 4 | Cowan ElviaSVP, Finance & CAOAward · Stock Option (right to buy) · $0 · 17,855 sh |
| Feb 26, 2026Form 4 | Cowan ElviaSVP, Finance & CAOAward · $0 · 10,681 sh |
| Feb 26, 2026Form 4 | Cowan ElviaSVP, Finance & CAOExercise or conversion · Stock Option (right to buy) · $0 · 7,716 sh |
| Jan 15, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · Stock Option (right to buy) · $0 · 6,750 sh |
| Jan 15, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · $0 · 1,357 sh |
| Jan 14, 2026Form 4 | GUGGENHIME ANDREWPRESIDENT AND CFOGift · $0 · 123,700 sh |
| Jan 14, 2026Form 4 | PICKERING GRANTCHIEF EXECUTIVE OFFICER · DirectorGift · $0 · 100,000 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 19 filings
| Filed | What it is |
|---|---|
| Nov 4, 202610-Q | Quarterly report, Q3 2026 — net income −$297.1M, EPS −$1.99 |
| Nov 4, 20268-K | Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business UpdateResults of operations |
| Oct 9, 20268-K | Material definitive agreement; New financial obligation; Other events |
| Oct 5, 20268-K | Regulation FD disclosure; Other events |
| Sep 3, 20268-K | Directors or officers; compensation; Regulation FD disclosure |
| Aug 5, 202610-Q | Quarterly report, Q2 2026 — net income −$284.3M, EPS −$1.97 |
| Aug 5, 20268-K | Earnings release — EPS −$1.97 vs −$1.47 est. (−34.0%) 5.3% |
| Jul 15, 20268-K | Directors or officers; compensation |
| Jun 23, 20268-K | Directors or officers; compensation |
| Jun 16, 20268-K | Shareholder vote results |
| May 6, 202610-Q | Quarterly report, Q1 2026 — net income −$320.6M, EPS −$2.30 |
| May 6, 20268-K | Earnings release — EPS −$2.30 vs −$1.86 est. (−23.7%) 9.8% |
| Apr 23, 2026ARS | Annual report to shareholders |
| Apr 23, 2026DEFA14A | Additional proxy materials |
| Apr 23, 2026DEF 14A | Proxy statement |
| Feb 24, 20268-K | Other events |
| Feb 24, 202610-K | Annual report, FY2025 — net income −$766.6M, EPS −$5.63 |
| Feb 24, 20268-K | Earnings release — EPS −$1.80 vs −$1.46 est. (−23.3%) 2.8% |
| Feb 2, 20268-K | Other events |
2025 · 17 filings
| Filed | What it is |
|---|---|
| Dec 19, 20258-K | Directors or officers; compensation |
| Nov 4, 202510-Q | Quarterly report, Q3 2025 — net income −$212.8M, EPS −$1.56 |
| Nov 4, 20258-K | Earnings release — EPS −$1.56 vs −$1.27 est. (−22.8%) 2.5% |
| Sep 30, 20258-K | Material definitive agreement |
| Aug 6, 202510-Q | Quarterly report, Q2 2025 — net income −$166.6M, EPS −$1.22 |
| Aug 6, 20258-K | Earnings release — EPS −$1.22 vs −$1.12 est. (−8.9%) 9.1% |
| Jun 17, 20258-K | Shareholder vote results |
| May 7, 202510-Q | Quarterly report, Q1 2025 — net income −$140.7M, EPS −$1.04 |
| May 7, 20258-K | Earnings release — EPS −$1.04 vs −$1.02 est. (−2.0%) 8.4% |
| May 1, 20258-K | Directors or officers; compensation |
| Apr 28, 2025ARS | Annual report to shareholders |
| Apr 28, 2025DEFA14A | Additional proxy materials |
| Apr 28, 2025DEF 14A | Proxy statement |
| Apr 18, 2025PRE 14A | Preliminary proxy statement |
| Mar 31, 20258-K | Regulation FD disclosure; Other events |
| Feb 25, 202510-K | Annual report, FY2024 — net income −$463.9M, EPS −$3.80 |
| Feb 25, 20258-K | Earnings release — EPS −$1.02 vs −$1.32 est. (+22.7%) 0.9% |
2024 · 17 filings
| Filed | What it is |
|---|---|
| Nov 21, 20248-K | Material definitive agreement; Other events |
| Nov 5, 202410-Q | Quarterly report, Q3 2024 — net income −$103.1M, EPS −$0.83 |
| Nov 5, 20248-K | Earnings release — EPS −$0.83 vs −$0.98 est. (+15.3%) 3.2% |
| Sep 6, 20248-K | Other events |
| Sep 3, 20248-K | Regulation FD disclosure; Other events |
| Aug 6, 202410-Q | Quarterly report, Q2 2024 — net income −$128.7M, EPS −$1.10 |
| Aug 6, 20248-K | Earnings release — EPS −$1.10 vs −$1.14 est. (+3.5%) 4.6% |
| Jul 2, 20248-K | Directors or officers; compensation |
| Jun 10, 20248-K | Shareholder vote results |
| May 8, 202410-Q | Quarterly report, Q1 2024 — net income −$95.0M, EPS −$0.85 |
| May 8, 20248-K | Earnings release — EPS −$0.85 vs −$1.11 est. (+23.4%) 1.8% |
| Apr 15, 2024ARS | Annual report to shareholders |
| Apr 15, 2024DEFA14A | Additional proxy materials |
| Apr 15, 2024DEF 14A | Proxy statement |
| Feb 27, 202410-K | Annual report, FY2023 — net income −$402.3M, EPS −$4.14 |
| Feb 27, 20248-K | Earnings release — EPS −$1.82 vs −$0.90 est. (−102.2%) 7.3% |
| Jan 31, 20248-K | Other events |
2023 · 21 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 6, 202310-Q | Quarterly report, Q3 2023 — net income −$92.7M, EPS −$0.91 |
| Aug 8, 202310-Q | Quarterly report, Q2 2023 — net income −$68.3M, EPS −$0.70 |
| May 8, 202310-Q | Quarterly report, Q1 2023 — net income −$60.5M, EPS −$0.70 |
| Apr 28, 2023ARS | Annual report to shareholders |
| Apr 28, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023DEF 14A | Proxy statement |
| Feb 27, 202310-K | Annual report, FY2022 — net income −$223.5M, EPS −$3.44 |
14 current reports (8-K) not listed; the year is on EDGAR.
2022 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 7, 202210-Q | Quarterly report, Q3 2022 — net income −$57.9M, EPS −$0.93 |
| Aug 8, 202210-Q | Quarterly report, Q2 2022 — net income −$48.5M, EPS −$0.80 |
| May 9, 202210-Q | Quarterly report, Q1 2022 — net income −$39.0M, EPS −$0.68 |
| Apr 20, 2022DEFA14A | Additional proxy materials |
| Apr 20, 2022DEF 14A | Proxy statement |
| Feb 28, 202210-K | Annual report, FY2021 — net income −$100.1M, EPS −$1.93 |
11 current reports (8-K) not listed; the year is on EDGAR.
2021 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 10, 202110-Q | Quarterly report, Q3 2021 — net income −$26.6M, EPS −$0.51 |
| Aug 11, 202110-Q | Quarterly report, Q2 2021 — net income −$23.7M, EPS −$0.46 |
| May 11, 202110-Q | Quarterly report, Q1 2021 — net income −$21.2M |
| Apr 14, 2021DEFA14A | Additional proxy materials |
| Apr 14, 2021DEF 14A | Proxy statement |
| Mar 29, 202110-K | Annual report, FY2020 — net income −$89.2M, EPS −$3.02 |
9 current reports (8-K) not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 100 filings — 54 × 4, 24 × 144, 8 × SCHEDULE 13G/A and 6 other forms
| Filed | What it is |
|---|---|
| Nov 4, 20264 | Insider transaction (Form 4) |
| Nov 4, 20264 | Insider transaction (Form 4) |
| Nov 2, 2026144 | Notice of proposed sale (Form 144) |
| Nov 2, 2026144 | Notice of proposed sale (Form 144) |
| Oct 8, 2026424B5 | Prospectus supplement |
| Oct 8, 2026424B5 | Prospectus supplement |
| Oct 7, 20264 | Insider transaction (Form 4) |
| Oct 7, 20264 | Insider transaction (Form 4) |
| Oct 7, 2026FWP | Free writing prospectus |
| Oct 6, 2026305B2 | Other filings |
| Oct 6, 2026424B5 | Prospectus supplement |
| Oct 6, 2026424B5 | Prospectus supplement |
| Oct 5, 2026144 | Notice of proposed sale (Form 144) |
| Oct 5, 2026144 | Notice of proposed sale (Form 144) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 1, 2026144 | Notice of proposed sale (Form 144) |
| Sep 9, 20264 | Insider transaction (Form 4) |
| Sep 9, 20264 | Insider transaction (Form 4) |
| Sep 9, 20264 | Insider transaction (Form 4) |
| Sep 9, 20264 | Insider transaction (Form 4) |
| Sep 9, 20264 | Insider transaction (Form 4) |
| Sep 9, 20264 | Insider transaction (Form 4) |
| Sep 9, 20263 | Initial insider holdings (Form 3) |
| Sep 9, 2026144 | Notice of proposed sale (Form 144) |
| Sep 4, 2026144 | Notice of proposed sale (Form 144) |
The newest 25 of 100 shown; the full year is on EDGAR.
2025 · 65 filings — 38 × 4, 11 × 144, 9 × SCHEDULE 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 31, 2025144 | Notice of proposed sale (Form 144) |
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 23, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 2025SCHEDULE 13G | Other filings |
| Nov 14, 2025SCHEDULE 13G/A | Other filings |
| Sep 10, 20254 | Insider transaction (Form 4) |
| Sep 10, 20254 | Insider transaction (Form 4) |
| Sep 10, 20254 | Insider transaction (Form 4) |
| Sep 10, 20254 | Insider transaction (Form 4) |
| Sep 10, 20254 | Insider transaction (Form 4) |
| Sep 8, 2025SCHEDULE 13G/A | Other filings |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Aug 29, 20254 | Insider transaction (Form 4) |
| Aug 14, 2025SCHEDULE 13G/A | Other filings |
| Aug 6, 2025SCHEDULE 13G/A | Other filings |
| Jun 16, 20254 | Insider transaction (Form 4) |
| Jun 16, 20254 | Insider transaction (Form 4) |
| Jun 16, 20254 | Insider transaction (Form 4) |
| Jun 16, 20254 | Insider transaction (Form 4) |
| Jun 16, 20254 | Insider transaction (Form 4) |
| Jun 16, 20254 | Insider transaction (Form 4) |
The newest 25 of 65 shown; the full year is on EDGAR.
2024 · 182 filings — 95 × 4, 71 × 144, 8 × SC 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 19, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 2024144 | Notice of proposed sale (Form 144) |
| Dec 10, 20244 | Insider transaction (Form 4) |
| Dec 10, 20244 | Insider transaction (Form 4) |
| Dec 9, 20244 | Insider transaction (Form 4) |
| Dec 9, 2024144 | Notice of proposed sale (Form 144) |
| Dec 5, 2024144 | Notice of proposed sale (Form 144) |
| Dec 3, 20244 | Insider transaction (Form 4) |
| Dec 3, 20244 | Insider transaction (Form 4) |
| Dec 2, 2024144 | Notice of proposed sale (Form 144) |
| Dec 2, 2024144 | Notice of proposed sale (Form 144) |
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 18, 2024144 | Notice of proposed sale (Form 144) |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 8, 20244 | Insider transaction (Form 4) |
| Nov 7, 2024144 | Notice of proposed sale (Form 144) |
| Nov 6, 20244 | Insider transaction (Form 4) |
The newest 25 of 182 shown; the full year is on EDGAR.
2023 · 78 filings — 46 × 4, 18 × 144, 6 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2022 · 85 filings — 68 × 4, 7 × SC 13G/A, 4 × 424B5 and 5 other forms
Counted, not listed; the year is on EDGAR.
2021 · 82 filings — 67 × 4, 5 × 3, 4 × SC 13G and 3 other forms
Counted, not listed; the year is on EDGAR.
2020 · 56 filings — 18 × 3, 17 × 4, 3 × CORRESP and 14 other forms
Counted, not listed; the year is on EDGAR.
2019 · 4 filings — 1 × DRS, 1 × DRS/A, 1 × DRSLTR and 1 other form
Counted, not listed; the year is on EDGAR.
2018 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
2017 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
2015 · 1 filing — 1 × D
Counted, not listed; the year is on EDGAR.
About this data#
Vaxcyte Inc. (PCVX) has 767 filings on EDGAR going back to 2015: 6 annual reports, 20 quarterly reports and 69 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Nov 4, 2026, furnished a press release headed “Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update”. Over the last 13 months insiders sold $12.2M in 25 sales and bought nothing on the open market; 100 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Vaxcyte Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
Head-to-head:Compare with ALNY or any ticker →
FAQ#
- Where can I read PCVX's latest 10-K?
- PCVX's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did PCVX last file an 8-K?
- On Nov 4, 2026 it furnished a press release headed “Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Nov 4, 2026.
- Are PCVX insiders buying or selling?
- Over the last 13 months insiders sold $12.2M in 25 sales and bought nothing on the open market; 100 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Cowan Elvia (SVP, Finance & CAO) sold 3,000 shares on Nov 2, 2026 for $183K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has PCVX made?
- 767 filings are on EDGAR under the registrant records that have been Vaxcyte Inc., going back to 2015; 546 of them are insider ownership forms (Forms 3, 4, 5 and 144).